SOV2012-F1

DRUG2 trials

Sponsors

Marius Pharmaceuticals

Conditions

Hypogonadism, Male

Phase 3

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

CompletedNCT03198728

Marius PharmaceuticalsHypogonadism, Male

Start: 2017-07-05End: 2020-05-01Updated: 2023-06-28

Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

CompletedNCT04467697

Marius PharmaceuticalsHypogonadism, Male

Start: 2018-09-18End: 2020-05-01Updated: 2024-06-28

Related Papers

A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product

Therapeutic Advances in Urology2024-01-012 citations

The Evolving Role of Novel Oral Agents for Testosterone Replacement Therapy; A Historical Perspective

Androgens Clinical Research and Therapeutics2022-12-013 citations

Effects of Oral Testosterone Undecanoate (Kyzatrex) Versus Testosterone Gel (Androgel) on Long-Term (to 12 Months) Blood Pressure Levels

Androgens Clinical Research and Therapeutics2022-12-011 citations